Author/Authors :
Aloke V. Finn، نويسنده , , Igor F. Palacios، نويسنده , , Adnan Kastrati، نويسنده , , Herman K. Gold، نويسنده ,
Abstract :
The two pivotal U.S. trials of drug-eluting stents do not establish the principle that these stents are superior to thin-strut bare-metal stents for preventing repeat revascularization in patients with diabetes. Neither study was adequately powered to make this determination. Moreover, both studies used thick-strut stents known to have high restenosis rates as controls. Low angiographic follow-up underestimates the true target lesion revascularization rate in the Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease (TAXUS-IV) trial because of the high incidence of silent ischemia in patients with diabetes. Optimal therapy for diabetic coronary disease should include a comprehensive approach directed toward metabolic normalization in addition to local stent-based therapy.
Keywords :
PCI , PPAR , DES , TLR , SES , PES , Percutaneous coronary intervention , Sirolimus-eluting stent , SIRIUS , target lesion revascularization , paclitaxel-eluting stent , BMS , bare-metal stent , drug-eluting stents , ISAR-STEREO , Intracoronary Stenting and Angiographic Results-Strut Thickness Effect on Restenosis Outcomes trial , peroxisome proliferator-activated receptor , RVD , reference vessel diameter , Sirolimus-coated BX Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Coronary Artery Lesions , TAXUS-IV , Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
